Document and Entity Information - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2016 |
Mar. 28, 2017 |
Jun. 30, 2016 |
|
| Document And Entity Information | |||
| Entity Registrant Name | GT Biopharma, Inc. | ||
| Entity Central Index Key | 0000109657 | ||
| Document Type | 10-K/A | ||
| Document Period End Date | Dec. 31, 2016 | ||
| Amendment Flag | true | ||
| Amendment Description |
GT Biopharma, Inc., formerly known as Oxis International, Inc, (the “Company”) is filing this Amendment No. 1 to its Annual Report on Form 10-K for its fiscal year ended December 31, 2016, as filed with the Securities and Exchange Commission on March 31, 2017 (the “Original December 2016 Form 10-K”), primarily to correct an error related to the non-cash calculation of warranty liabilities.
Actual Changes in the Original December 2016 Form 10-K. The actual changes in the Original December Form 10-K included in this Amendment No. 1 are amendments to Part II that include: (a) amended and restated Consolidated Statement of Operations for the year ended December 31, 2016, (b) amended and restated Consolidated Statement of Stockholders’ Deficit for the year ended December 31, 2016, (c) amended and restated Consolidated Statement of Cash Flows for the year ended December 31, 2016, and (d) the addition of Note 6.
Notwithstanding that there are no changes in most of the Notes to the Consolidated Financial Statements included in this Amendment No. 1, a complete Form 10-K document including a complete set of the Consolidated Financial Statements (together with all of the Notes from the Original December 2016 10-K) has been included in this Amendment No. 1, for convenient reference.
In addition, see additional amended filings of the Company for relevant subsequent events. |
||
| Current Fiscal Year End Date | --12-31 | ||
| Is Entity a Well-known Seasoned Issuer? | No | ||
| Is Entity a Voluntary Filer? | No | ||
| Is Entity's Reporting Status Current? | Yes | ||
| Entity Filer Category | Smaller Reporting Company | ||
| Entity Public Float | $ 93,000,000 | ||
| Entity Common Stock, Shares Outstanding | 122,912,868 | ||
| Document Fiscal Period Focus | FY | ||
| Document Fiscal Year Focus | 2016 |